Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience

医学 轮廓 鼻咽癌 放射治疗 阶段(地层学) 置信区间 原发性肿瘤 核医学 外科 放射科 癌症 转移 内科学 工程类 古生物学 工程制图 生物
作者
Nina N. Sanford,Jackson Lau,Miranda B. Lam,Amy F. Juliano,Judith Adams,Saveli Goldberg,Hsiao-Ming Lu,Yue Lü,Norbert J. Liebsch,Hugh D. Curtin,Annie W. Chan
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:103 (3): 654-668 被引量:42
标识
DOI:10.1016/j.ijrobp.2018.10.006
摘要

Purpose Radiation-related toxicity in nasopharyngeal carcinoma (NPC) is common. There are no well-established guidelines for clinical target volume (CTV) delineation with long-term follow-up. Current consensus continues to rely heavily on bony landmarks and fixed margins around the gross tumor volume (GTV), an approach used to define fields in the conventional 2- and 3-dimensional radiation therapy era. Methods and Materials We retrospectively evaluated patients with newly diagnosed nonmetastatic NPC treated with definitive radiation therapy using a technique of CTV delineation based on individual tumor extent and the orderly stepwise pattern of tumor spread. Dosimetric comparisons were made between national protocol HN001 and our contouring strategies on a representative early- and advanced-stage NPC. The primary endpoints were patterns of failure and local control; secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. Results Between 1999 and 2013, 73 patients (88% with stage 3-4 disease) were treated with median follow-up of 90 months for surviving patients. Median dose to GTV was 70 Gy. Four patients developed local recurrence and 1 patient developed regional recurrence. All locoregional recurrences occurred within the high-dose GTV. The 5-year local control, regional control, and overall survival was 94% (95% confidence interval [CI], 85%-98%), 99% (95% CI, 90%-100%), and 84% (95% CI, 73%-91%), respectively. Compared with HN001, our contouring strategy resulted in 62% and 36% reduction in CTV for T1 and T4 disease, respectively. In the T1 tumor, the reduction of doses to the contralateral parotid, optic nerve, and cochlea were 54%, 50%, 34% respectively. In the T4 case, there was a decrease of optic chiasm dose of 46% and contralateral optic nerve of 37%. There were 10 grade 3 toxicities. There was no grade 2 or higher xerostomia and no grade 4/5 toxicity. Conclusions Our long-term experience with individualized CTV delineation based on stepwise patterns of spread results in excellent local control, with no recurrence outside the GTV. Radiation-related toxicity in nasopharyngeal carcinoma (NPC) is common. There are no well-established guidelines for clinical target volume (CTV) delineation with long-term follow-up. Current consensus continues to rely heavily on bony landmarks and fixed margins around the gross tumor volume (GTV), an approach used to define fields in the conventional 2- and 3-dimensional radiation therapy era. We retrospectively evaluated patients with newly diagnosed nonmetastatic NPC treated with definitive radiation therapy using a technique of CTV delineation based on individual tumor extent and the orderly stepwise pattern of tumor spread. Dosimetric comparisons were made between national protocol HN001 and our contouring strategies on a representative early- and advanced-stage NPC. The primary endpoints were patterns of failure and local control; secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. Between 1999 and 2013, 73 patients (88% with stage 3-4 disease) were treated with median follow-up of 90 months for surviving patients. Median dose to GTV was 70 Gy. Four patients developed local recurrence and 1 patient developed regional recurrence. All locoregional recurrences occurred within the high-dose GTV. The 5-year local control, regional control, and overall survival was 94% (95% confidence interval [CI], 85%-98%), 99% (95% CI, 90%-100%), and 84% (95% CI, 73%-91%), respectively. Compared with HN001, our contouring strategy resulted in 62% and 36% reduction in CTV for T1 and T4 disease, respectively. In the T1 tumor, the reduction of doses to the contralateral parotid, optic nerve, and cochlea were 54%, 50%, 34% respectively. In the T4 case, there was a decrease of optic chiasm dose of 46% and contralateral optic nerve of 37%. There were 10 grade 3 toxicities. There was no grade 2 or higher xerostomia and no grade 4/5 toxicity. Our long-term experience with individualized CTV delineation based on stepwise patterns of spread results in excellent local control, with no recurrence outside the GTV.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
青菜完成签到,获得积分10
1秒前
萝卜完成签到,获得积分10
1秒前
正直的若风关注了科研通微信公众号
2秒前
科研渣渣发布了新的文献求助10
3秒前
zlt完成签到,获得积分10
4秒前
张图门完成签到 ,获得积分10
4秒前
寒冷的迎梦完成签到,获得积分10
4秒前
5秒前
St雪完成签到,获得积分10
5秒前
陈琛琛完成签到,获得积分10
5秒前
幽默的煎饼完成签到,获得积分10
5秒前
就想按时下班完成签到,获得积分10
7秒前
FFFFFFG完成签到,获得积分10
7秒前
大连理工官方完成签到,获得积分10
7秒前
章梦竹完成签到,获得积分10
8秒前
梅赛德斯奔驰完成签到,获得积分10
10秒前
隐形草丛完成签到,获得积分10
14秒前
四喜丸子应助oioi采纳,获得10
14秒前
Rayson完成签到,获得积分10
14秒前
钱塘郎中完成签到,获得积分0
15秒前
大力的冬萱完成签到,获得积分0
16秒前
鲲鹏完成签到 ,获得积分10
16秒前
YONGLI完成签到,获得积分10
18秒前
18秒前
18秒前
18秒前
飞快的迎南完成签到,获得积分10
18秒前
年轻秋烟完成签到,获得积分10
20秒前
20秒前
付华完成签到,获得积分10
21秒前
Zeusqwer完成签到 ,获得积分10
23秒前
文艺香旋完成签到,获得积分10
23秒前
贤惠的人龙完成签到,获得积分10
23秒前
oioi完成签到,获得积分10
24秒前
李查查完成签到 ,获得积分10
26秒前
CipherSage应助欣慰的源智采纳,获得10
26秒前
QDU发布了新的文献求助10
27秒前
夏夜完成签到 ,获得积分10
27秒前
李健应助能干的馒头采纳,获得20
27秒前
杨涵完成签到 ,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
核安全综合知识2024版 500
Photothermal Science and Techniques 500
Digital Displacement Hydrostatic Transmission for Rotorcraft and Distributed Propulsion 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7705957
求助须知:如何正确求助?哪些是违规求助? 9263537
关于积分的说明 20043323
捐赠科研通 7281856
什么是DOI,文献DOI怎么找? 3295394
关于科研通互助平台的介绍 2450580
邀请新用户注册赠送积分活动 2302421